Who is sponsoring NCT06350903?

NCT06350903 is sponsored by Matthieu Pelletier-Galarneau, MD MSc.

What drugs are being tested in NCT06350903?

Interventions in NCT06350903: Fast + High-fat low-carbohydrate diet, Fast + Empagliflozin.

What condition does NCT06350903 study?

NCT06350903 studies Myocardial Suppression.

Is NCT06350903 still recruiting?

NCT06350903 is currently completed. Last updated 29 September 2025.

Last reviewed 2025-09-29 · How we verify

NCT06350903: SWEET-HEART

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Suppression With Empagliflozin as an Alternative To High-Fat Low-Carbohydrate Diet for Myocardial F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Imaging

Completed NA Last updated 29 September 2025

What this trial tests

NA trial testing Fast + High-fat low-carbohydrate diet in Myocardial Suppression in 16 participants. Completed in 1 November 2024.

Timeline

1 June 2024

Primary endpoint
1 November 2024

1 November 2024

Quick facts

Lead sponsor	Matthieu Pelletier-Galarneau, MD MSc
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	diagnostic
Enrollment	16
Start date	1 June 2024
Primary completion	1 November 2024
Estimated completion	1 November 2024
Sites	1 location across Canada

Drugs / interventions tested

Fast + High-fat low-carbohydrate diet
Fast + Empagliflozin

Conditions studied

Myocardial Suppression — all drugs for Myocardial Suppression →

Sponsor

Matthieu Pelletier-Galarneau, MD MSc

Who can join

Adults 18 to 70, any sex, with Myocardial Suppression. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The overall objective of this study is to assess if the empagliflozin has the potential to substitute the high fat low carb (HFLC) diet for the preparation of cardiovascular FDG-PET studies.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Matthieu Pelletier-Galarneau, MD MSc trials

Trials by the same sponsor.

NCT06332456 — Assessment of Renal Microcirculation With Rubidium Positron Emission Tomography · completed
NCT06353009 — Effect of a Single Ultra-Processed Meal on Myocardial Endothelial Function Assessed With Positron Emission Tomography · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06350903 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Matthieu Pelletier-Galarneau, MD MSc
Last refreshed: 29 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06350903.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing